PDA Technical Report No. 27: Pharmaceutical Package Integrity

, titled "Pharmaceutical Package Integrity," is a foundational guidance document published by the Parenteral Drug Association (PDA) that establishes best practices for ensuring the barrier qualities of pharmaceutical packaging. Originally released in 1998 to supersede Technical Information Bulletin No. 4, it remains a critical reference for manufacturers developing strategies to protect sterile products from environmental contamination and maintain product stability throughout their lifecycle. Key Objectives of TR 27

For professionals seeking the full technical details, the PDA Bookstore offers the for purchase and download. Technical Report No. 27: Pharmaceutical Package Integrity

: Regular monitoring during production, such as visual inspections and automated leak detection, helps identify defects early.

: Often considered the gold standard for validating a sterile barrier.

: A traditional physical method often correlated to microbial results.

: TR 27 advocates for an integrity assessment that begins during the design phase and continues through routine manufacturing and shelf-life stability testing.

: Manufacturers must establish acceptable ranges for critical variables (e.g., heat seal temperature or pressure) and evaluate their impact on integrity using exaggerated "worst-case" conditions.